Every parent wants a healthy start for their baby. But for too many families around the world, this principle is characterized by uncertainty. Each year, millions of babies are born very soon or too young – and for many, it is a matter of life or death.
Globally, one in four newborns are either premature, low birth weight or is young for their pregnancy age. These babies face a greater risk of complications and death in the first weeks of life. In fact, prediction is now the leading cause of death in children under five years.
What causes these poor results? There are many factors, but one of the biggest culprits is often invisible: maternal infection and inflammation during pregnancy. This is especially true for mothers living with HIV, whose babies are more likely to be born very early or too young.
A new study by Zimbabwe suggests that a surprisingly simple intervention could help: a daily dose of a widely available antibiotic.
An international team of researchers led by Professor Andrew Prendergast from London’s Queen Mary University and Bernard Chasekwa from the Zvitambo Institute in Zimbabwe wanted to find out if the provision of pregnant women a daily antibiotic called TMP improve the results for their babies.
TMP-SMX is not new. It has been safely used for decades to prevent infections, especially in people living with HIV. It is cheap, easy to access and has anti-inflammatory properties-which make it a strong candidate to reduce the complications of pregnancy associated with infection.
The test, known as COMBI (Cotrimoxazole for mothers to improve birth weight in infants), included 993 pregnant women in rural Zimbabwe. Starting in their second trimester, women were randomly commissioned to receive either TMP-SMX or placebo daily until delivery.
The researchers were mainly trying to see if the antibiotic would increase the weight of birth. And on this front, the results were a bit disappointing. Babies in the TMP-SMX group weigh, on average, just 20 grams more than those of the placebo group-not a significant difference.
But when he came to premature birth, the findings were much more urgent.
- Only 6.9% of women in the TMP-SMX group delivered prematurely (37 weeks ago).
- This is compared to 11.5% in the placebo group.
- Not a single woman was delivered to the TMP-SMX 28 weeks ago, while five in the placebo group did.
For a drug already used and well understood, this is an important difference.
The impact was even more impressive among the 131 women in the study living with HIV:
- Only 2% of HIV-positive female female receiving TMP-SMX delivered prematurely,
- Compared to 14% of them in the placebo group.
- Their babies were also on average, 177 grams heavier.
While the burden of birth has not improved, researchers believe that this fall in premature births deserves more careful attention.
“Our test, which was conducted in the routine of prenatal care and the registration of women mainly from the rural areas, showed that trimethoprim -sulfamethoxazole did not improve the burden of birth, which was the main result,” said Bernard. “However, there has been an interesting proposal that it may have improved pregnancy length and reduce the rate of premature births.”
Professor Andrew Prendergast added:
“Our findings indicate that a low -cost, daily antibiotic, in an environment where infections such as HIV are common, could reduce the risk of premature births.
Sophie Hawkesworth from Wellcome, one of the studies of the study, underlined the broader impact:
“If we are to reduce the mortality of children worldwide, it is crucial to reduce the risk of premature births, especially in areas with limited access to intensive neonatal units. This is a very promising study … The prospect that this treatment prevents premature births justifies further study.”
In many parts of the world, early examination and treatment for infections during pregnancy is not always available. The TMP-SMX could offer a simple, scaled solution-especially in areas where HIV is common and early birth rates are high.
What makes these findings so encouraging is that TMP-SMX is:
- Safe When used after the first trimester,
- Cheap (already widely distributed throughout the sub -Saharan Africa),
- And Easy to manage.
It’s not a new or experimental drug – it’s what healthcare providers are already familiar.
This study does not provide a complete solution, but opens a promising door. With focus during pregnancy rather than birth weight, it highlights one key point: a few additional weeks in the uterus may be rescue.
While this was a well -designed randomized controlled test, the researchers note that further studies are required:
- To confirm the connection between TMP-SMX and reduced premature birth,
- To check whether the start of the drug earlier during pregnancy offers even greater protection,
- And evaluate the results in other countries and in healthcare environments.
As Chasekwa put it, “we now have to repeat this test in different settings around the world to see if antibiotics during pregnancy can help reduce early life.”
This study did not give the result originally defined to find – higher birth weights – but may have revealed something more important: a simple, accessible way to reduce the risk of premature birth.
In places where neonatal care is limited, prevention of first delivery in the first place could make the whole difference.
At present, the results are promising. If the larger studies confirm these findings, TMP-SMX could become a valuable tool for reducing newborn deaths and helping babies around the world begin better in life.
Sources:
Pregnancy Package
This post includes subsidiaries where we will receive a small percentage if you buy through the link.
